Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	ILA 249.30	+3.02%	37,823
26-07-22	ILA 242.00	-5.62%	169,131
26-07-21	ILA 256.40	-3.54%	23,094
26-07-20	ILA 265.80	+1.80%	155,380

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 06:44:24 2026-07-24 am EDT			5-day change	1st Jan Change
249.30 ^ILa	+3.02%		-4.52%	-54.75%

Jul. 09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
Jun. 22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI

Market Cap	72.91M 7.29B 23.93M 21M 19.55M 17.9M 33.66M 2.31B 34.21M 232M 90.66M 1.13B 89.82M 87.9M 3.92B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	52.77M 5.28B 17.32M 15.2M 14.15M 12.95M 24.36M 1.67B 24.76M 168M 65.61M 820M 65.01M 63.62M 2.84B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

Jul. 09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
Jun. 22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
Jun. 17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
Mar. 30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
Mar. 24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
Mar. 23	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
Mar. 04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
Mar. 03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
Mar. 03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
Feb. 27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
25-08-03	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-11	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

Jul. 09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
Jun. 23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
Mar. 03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
Mar. 02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
Feb. 27	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+3.02%
1 week	-4.52%
Current month	-8.71%
1 month	-14.18%
3 months	-10.39%
6 months	-58.18%
Current year	-54.75%

1 week	233.1	270
1 month	233.1	289.8
Current year	212	853
1 year	204	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	2019-05-31
Asaf Toker CEO	Chief Executive Officer	53	2019-05-31
Alon Sinai COO	Chief Operating Officer	58	2019-06-30

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	58	2019-06-30
Tal Dvir BRD	Director/Board Member	51	2019-05-31
Stanley Hirsch BRD	Director/Board Member	68	2022-07-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+3.02%	-4.52%	+9.20%	-38.57%	23.94M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+10.44%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+634.87%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+65.64%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.16%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+40.92%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.36%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.03%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-33.61%	12.7B
Average	+0.50%	+0.30%	+49.52%	+90.33%	24.53B
Weighted average by Cap.	+0.48%	+0.91%	+74.41%	+136.26%

	2024	2025
Net sales	-	-
Net income	-15.58M -1.56B -5.12M -4.49M -4.18M -3.82M -7.19M -494M -7.31M -49.54M -19.38M -242M -19.2M -18.79M -837M	-27.82M -2.78B -9.13M -8.02M -7.46M -6.83M -12.84M -882M -13.06M -88.46M -34.59M -432M -34.27M -33.54M -1.49B
Net Debt	-10.68M -1.07B -3.51M -3.08M -2.86M -2.62M -4.93M -339M -5.01M -33.96M -13.28M -166M -13.16M -12.88M -574M	-20.14M -2.01B -6.61M -5.8M -5.4M -4.94M -9.3M -638M -9.45M -64.03M -25.04M -313M -24.81M -24.28M -1.08B